6 reports of this reaction
10.2% of all BEVACIZUMAB TNJN reports
#2 most reported adverse reaction
MYELOSUPPRESSION is the #2 most commonly reported adverse reaction for BEVACIZUMAB TNJN, manufactured by Bio-Thera Solutions, Ltd.. There are 6 FDA adverse event reports linking BEVACIZUMAB TNJN to MYELOSUPPRESSION. This represents approximately 10.2% of all 59 adverse event reports for this drug.
Patients taking BEVACIZUMAB TNJN who experience myelosuppression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELOSUPPRESSION is a frequently reported adverse event for BEVACIZUMAB TNJN, accounting for a significant proportion of all reports.
In addition to myelosuppression, the following adverse reactions have been reported for BEVACIZUMAB TNJN:
The following drugs have also been linked to myelosuppression in FDA adverse event reports:
MYELOSUPPRESSION has been reported as an adverse event in 6 FDA reports for BEVACIZUMAB TNJN. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELOSUPPRESSION accounts for approximately 10.2% of all adverse event reports for BEVACIZUMAB TNJN, making it one of the most commonly reported side effect.
If you experience myelosuppression while taking BEVACIZUMAB TNJN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.